Patent ID: 11951113
Assignee: NEURALIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 7:
8. The combination composition according to claim 7, wherein said neurodegenerative disease or condition is selected from the group consisting of: Alzheimer's disease (AD), senile dementia of AD type (SDAT), Parkinson's disease and all parkinsonian syndromes, Lewis body dementia, mild cognitive impairment (MCI), age-associated memory impairment (AAMI) and problem associated with ageing, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, corticobasal ganglionic degeneration, multiple system atrophy, cerebral atrophy, olivopontocerebellar atrophy, supranuclear palsy, Niemann-Pick of type A disease, Pick diseases, traumatic neurodegeneration, Friedreich's ataxia, spinocerebellar ataxia type 2, Fahr's syndrome, Joubert syndrome, Huntington's disease, polyglutamine disease, dentatorubral atrophy, pallidoluysian atrophy, spinobulbar atrophy, myotonic dystrophy, Machado-Joseph's disease, amyotrophic lateral sclerosis (ALS), myasthenia gravis, Lambert Eaton's disease, infantile spinal amyotrophy or progressive spinal amyotrophy, motor-sensory neurodegeneration, multiple sclerosis, Guillain-Barre's syndrome, Charcot-Marie-Tooth disease (type 1 and 4), Progressive Multifocal Leukoencephalopathy (PML), leukodystrophic diseases, such as metachromatic leukodystrophy and adrenoleukodystrophy, Alexander's disease, Krabbe's disease, Zellweger's disease, Canavan disease, Pelizaeus-Merzbacher's syndrome, adrenomyeloneuropathy, neuropathies including hereditary neuropathy, diabetic neuropathy and anti-mitotic neuropathy.